Nucana Plc ADR (NCNA) Stock Price, Quote & News

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 13 1357 1111

Website: www.nucana.com

Address:

3 Lochside Way, Edinburgh, United Kingdom

Benja69 Feb. 24 at 5:46 PM

$NCNA

0 · Reply

cycloon Feb. 24 at 4:09 PM

$NCNA

0 · Reply

GreenEnergy1 Feb. 24 at 4:00 PM

$NCNA All this trash… Buy all that you want.. haha

0 · Reply

cycloon Feb. 24 at 3:17 PM

$NCNA

0 · Reply

cycloon Feb. 24 at 3:00 PM

$NCNA

0 · Reply

ChickenClaw Feb. 24 at 1:36 PM

$NCNA Hopefully Bruce/Hugh Have Their New Shares Allotted To Them For Their New/Reset Positions...So Then Now This Will Be Set To Take Off.

1 · Reply

ChickenClaw Feb. 24 at 1:29 PM

$NCNA Sumpdin Fishey Bout Green Monkay....Cheer Ta Looze Money...Maka Noa senzi.

0 · Reply

bills7765 Feb. 24 at 10:46 AM

$NCNA Price is staying in narrow range. Fintel shows 80k Short went to 0 then back to 80k last night. Not sure institutions are loaning shares or what the deal is. Price should be 1.50 Will no volume but its staying at or around 2 then bouncing then going back down. They are trying to discourage.

0 · Reply

GreenEnergy1 Feb. 23 at 11:22 PM

$NCNA Another 52 week low…

0 · Reply

GreenEnergy1 Feb. 23 at 6:17 PM

$NCNA In just 1 year this company has lost 99.06% Forecasted price is ZERO

0 · Reply

NuCana Appoints Theresa Bruce as Chief Operating Officer

Dec 10, 2025, 8:00 AM EST - 2 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Nov 13, 2025, 4:01 PM EST - 3 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:00 AM EST - 3 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Sep 5, 2025, 8:00 AM EDT - 6 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 3, 2025, 8:00 AM EDT - 6 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Aug 20, 2025, 4:05 PM EDT - 6 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 1, 2025, 4:05 PM EDT - 7 months ago

NuCana Announces ADS Ratio Change

Jul 21, 2025, 8:05 AM EDT - 7 months ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 11, 2025, 10:30 AM EDT - 8 months ago

NuCana Announces Plan to Implement ADS Ratio Change

Jun 2, 2025, 4:01 PM EDT - 9 months ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024$

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

May 30, 2024, 8:36 AM EDT - 1 year ago

NuCana to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 1 year ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 16, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 4:01 PM EDT - 1 year ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Jan 3, 2024, 2:39 AM EST - 2 years ago

NuCana: Potential Turnaround In 2024 But Risky

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 8:00 AM EDT - 2 years ago

NuCana to Present at the Jefferies Healthcare Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

Jan 8, 2023, 4:30 AM EST - 3 years ago

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Sep 22, 2022, 3:40 PM EDT - 3 years ago

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Benja69 Feb. 24 at 5:46 PM

$NCNA

0 · Reply

cycloon Feb. 24 at 4:09 PM

$NCNA

0 · Reply

GreenEnergy1 Feb. 24 at 4:00 PM

$NCNA All this trash… Buy all that you want.. haha

0 · Reply

cycloon Feb. 24 at 3:17 PM

$NCNA

0 · Reply

cycloon Feb. 24 at 3:00 PM

$NCNA

0 · Reply

ChickenClaw Feb. 24 at 1:36 PM

$NCNA Hopefully Bruce/Hugh Have Their New Shares Allotted To Them For Their New/Reset Positions...So Then Now This Will Be Set To Take Off.

1 · Reply

ChickenClaw Feb. 24 at 1:29 PM

$NCNA Sumpdin Fishey Bout Green Monkay....Cheer Ta Looze Money...Maka Noa senzi.

0 · Reply

bills7765 Feb. 24 at 10:46 AM

0 · Reply

GreenEnergy1 Feb. 23 at 11:22 PM

$NCNA Another 52 week low…

0 · Reply

GreenEnergy1 Feb. 23 at 6:17 PM

$NCNA In just 1 year this company has lost 99.06% Forecasted price is ZERO

0 · Reply

FickleFin Feb. 23 at 5:57 PM

$NCNA

0 · Reply

Antoor Feb. 23 at 4:16 PM

$NCNA what’s a realistic price target other than 0 for this?

1 · Reply

bills7765 Feb. 21 at 2:59 PM

$NCNA all value at this price. $2 seems to be rock solid. We should be getting after this right now. Not

0 · Reply

FredricBaines648 Feb. 21 at 6:25 AM

$NCNA NuCana develops oncology therapeutics. Clinical validation is required. Funding risk is significant.

0 · Reply

GreenEnergy1 Feb. 20 at 8:12 PM

$NCNA Another Red day and the volume is pitiful! Absolutely no interest in Nucana anywhere…

0 · Reply

Smug_Vortex Feb. 20 at 4:43 PM

$NCNA There’s buying, but the volume is weak. A catalyst would help. Hey management…hello?

0 · Reply

cycloon Feb. 20 at 4:36 PM

$NCNA When it comes to positive news, you have to have them, otherwise you're too late for the explosion.

0 · Reply

Spc_baller Feb. 20 at 4:36 PM

$NCNA am I a fool for buying more stock 🤭

1 · Reply

cycloon Feb. 20 at 3:24 PM

$NCNA Come on, don't look, buy and become rich.

0 · Reply

ChickenClaw Feb. 20 at 3:06 PM

$NCNA Im Here Post Stock Split And Feel The Numbers On This Stock Look AWESOME...Cash On Hand/Share Count Ratio.

1 · Reply

Panicmode Feb. 20 at 1:26 PM

$NCNA funny how all the pre RS pumpers have vanished that held threw the split and that nasty ADR fee.. when you read the history about this company from the beginning to here you know to stay away..

1 · Reply

GI812 Feb. 20 at 5:40 AM

$NCNA The No News thing is extremely aggravating. I'm not the only one Hughie you A-hole.

0 · Reply

Market Cap	64,000.00
Revenue (ttm)	0.00
Net Income (ttm)	-24.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	21,600
Avg Vol	68,936
Day's Range	N/A - N/A
Shares Out	30,000.00
Stochastic %K	21%
Beta	1.68
Analysts	Strong Buy
Price Target	$25.00